BioNexus Gene Lab Corp.
BGLC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.5% | 5.8% | -15.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 14.8% | 16.3% | 16.1% | 12.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | -$0 |
| SG&A Expenses | -$0 | $0 | -$0 | $0 |
| Sales & Mktg Exp. | -$0 | $0 | -$0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27.6% | -27% | -28.9% | -16.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27.9% | -27.3% | -29.2% | -13.8% |
| EPS | -0.39 | -0.34 | -0.35 | -0.19 |
| % Growth | -14.7% | 2.9% | -84.2% | – |
| EPS Diluted | -0.39 | -0.34 | -0.35 | -0.19 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -26.2% | -25.2% | -25.6% | -14.8% |